study question: Is thin endometrium unresponsive to standard treatments expandable by intrauterine perfusion with granulocyte colony-stimulating factor (G-CSF)?
Introduction
Chronically thin endometrium resistant to standard treatments affects a small number of patients undergoing IVF. This problem, nevertheless, is of considerable importance because endometrium below 7 mm in thickness is widely considered sub-optimal for transfer and associated with reduced pregnancy chances (Casper, 2011; Singh et al., 2011; Revel, 2012) .
Various remedies have been proposed, including extended estrogen administration if time allows (Chen et al., 2006) , low-dose aspirin (Weckstein et al., 1997) and treatment with pentoxifylline and tocopherol (Lédée-Bataille et al., 2002) and with vaginal sildenafil citrate (Viagra TM ) (Sher and Fisch, 2002) . However, even utilizing these remedies, a small number of women remain unresponsive.
The prevalence of patients who remain unresponsive to such standard treatment modalities is unknown but on the basis of our own (unpublished) experience, we have estimated it to be ,1% of the IVF patients. However, for such patients and their treating physicians, such a chronically thin endometrium offers considerable treatment challenges, resulting in cycle cancellations, unplanned cryopreservation of embryos and, in the most extreme cases, in the utilization of gestational carriers.
We previously reported the successful use of granulocyte colony-stimulating factor (G-CSF) in four IVF cycles, in which standard treatments to reach a minimal endometrial thickness of 7 mm had failed (Gleicher et al., 2011) . This preliminary experience led to the initiation of two prospectively RCTs of G-CSF at our center.
In our first four reported cases of G-CSF treatment, all the women conceived (one an intramural ectopic pregnancy), and therefore, in a first trial (NCT01202656) we decided to investigate whether endometrial perfusion with G-CSF, independent of endometrial thickness, in routine IVF cycles affects pregnancy rates. This trial is still underway, with approximately three-quarters of targeted cycles completed.
In a second clinical trial (NCT01202643), we planned to investigate in a prospectively randomized fashion whether, and to what degree, endometrial perfusion with G-CSF, indeed, is able to expand chronically thin endometrium, which is resistant to standard therapies. This trial is also still underway but recruitment is exceedingly slow and completion of this study is, therefore, not in the near future.
Therefore, as an interim step, here we report a series of 21 IVF cycles in women with chronically thin endometrium, who were treated with G-CSF outside the aforementioned trials because patients either did not qualify for the studies or refused participation.
Materials and Methods
We here report on 21 women in their first IVF cycle at our center. All the women on the day of ovulation induction with hCG demonstrated via ultrasound an endometrial thickness of ,7 mm, despite treatment with oral and vaginal ethinyl estradiol (E 2 ; 2 mg, per os twice daily and 1 mg per vagina three times daily) and sildenafil citrate (Viagra TM , 25 mg, per vagina four times daily, Pfizer Inc., New York, NY, USA).
At the time of this study, two registered prospective RCTs were being conducted at our center (ClinicalTrials.gov ID NCT01202643 and ClinicalTrials.gov ID NCT01202656), as already described, and the patients described here refused participation in the first and were unqualified for participation in the second trial. They, therefore, were given the following options: (i) participation in a clinical trial (for details see Materials and Methods); (ii) IVF cycle cancellation; (iii) embryo transfer into an inadequately thin endometrium and (iv) the off-label use of G-CSF in the form of an intrauterine infusion as already mentioned. All the patients selected option (iv). Table I summarizes the patient characteristics: Commensurate with our center's patient population, the mean + SD age of patients was 40.5 + 6.6 years; their BMI was 23.6 + 4.0. Their mean gravidity was 1.8 + 2.1 (range 0 -7) and their mean parity 0.4 + 1.1 (range 0 -4). The cycles reported here represent exclusively the first cycles at our center, but it is important to point out that these patients had previously undergone 2.0 + 2.1 IVF cycles elsewhere. The most common primary infertility diagnosis was diminished ovarian reserve, present in 16 (76.2%) of the women. A diagnosis of unresponsive thin endometrium was made on the day of administration of 10 000 IU hCG. Considering the adverse endometrial thickness in these patients, ovulation induction was induced even if only one follicle reached 19 mm. Once the decision to administer hCG in an IVF cycle was made after morning monitoring by ultrasound, women with endometrial thickness ,7 mm were asked to select one of the aforementioned four options. Once they decided to proceed with off-label use of G-CSF, they received an endometrial infusion (by tomcat catheter) of 30 mU (300 mcg/1 ml) of G-CSF (Neupogen TM , Filgastrim, Amgen Inc., Thousand Oaks, CA, USA) approximately 6 -12 h before hCG administration.
The infusion was administered as previously described (Gleicher et al., 2011) . In short, the content of the ampule was aspirated into a 1-ml insulin syringe, the Tomcat catheter was introduced into the endometrial cavity as performed during an intrauterine insemination and the content of the syringe was slowly injected into the cavity, while the catheter was gently moved back and forth. Upon completion of the injection, the syringe was disconnected, a small amount of air was aspirated, the syringe was reconnected to the catheter and the air bubble was injected, to pass whatever small amount of G-CSG was left in the Tomcat catheter into the endometrial cavity.
Two days later, during oocyte retrieval, the endometrial thickness was reassessed by ultrasound. If at that point the maximal endometrial thickness was still below 7 mm, a second, identical infusion of G-CSF was performed following oocyte retrieval. This was required only in 3/21 (14.3%) of cases.
A final endometrial measurement was made on the day of embryo transfer (universally Day 3). Endometrial thickness was always measured at the thickest point.
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS), version 18.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were presented as mean and SD and assessed by t-test. A P-value of , 0.05 was considered significant.
As noted earlier, patients in this study did not participate in our clinical trials of G-CSF, approved by the Institute Review Board. They received G-CSF infusion off-label and provided informed consent for the procedure we described as 'experimental.' All the patients also signed an informed consent that allows review of their medical records for research purposes, as long as the patient's anonymity and confidentiality of her medical record are maintained. Both conditions were met here.
Results
Our center cancels embryo transfers and cryopreserves all embryos if endometrial thickness on the day of embryo transfer is not at least 7 mm. All the patients underwent transfer. The clinical pregnancy rate in treated cycles was 19.1%.
None of the patient characteristics listed in Table I varied between conception (n ¼ 4) and non-conception (n ¼ 17) cycles. While this makes a contribution of other unrecognized factors to pregnancy success unlikely, the small study size does not preclude type II errors. Table II summarizes the endometrial findings before and after G-CSG perfusion: As the table demonstrates, for all the patients the average time between first G-CSF infusion and embryo transfer was 5.2 + 1.9 days. There was no difference between women who conceived and those who did not.
At the time of the first infusion, the endometrium thickness was 6.4 + 1.4 mm. By the time of embryo transfer, it had expanded to 9.3 + 2.1 mm (P , 0.001). There was also a significant difference between measurements at the time of the first infusion versus embryo transfer in cycles leading to pregnancy (P ¼ 0.034) and those not resulting in pregnancy (P , 0.001). The change in endometrial thickness for the whole group was 2.9 + 2.0 mm.
Discussion
Despite the small cohort size and lack of a control group, the present data are supportive of our initial report in which we suggested that endometrial perfusion with G-CSF may be effective in expanding chronically unresponsive thin endometrium, which was resistant to traditional remedies, such as increased E 2 support and Viagra TM (Gleicher et al., 2011) .
By presenting 21 first cycles of IVF treatment at our center in 21 women, we (for the first time) are able to report statistically sound data, which demonstrate a significant improvement in endometrial thickness after G-CSF treatment. As the study did not involve a control group, one could argue that the endometrium may have expanded even without G-CSF perfusions. Considering, however, that all the patients still presented with endometrium ,7 mm on the day of hCG and that prior attempts to thicken their endometrium with E 2 and Viagra TM had failed, such an explanation appears highly unlikely. Moreover, 0.1 + 0.4 (range 0-1) of previously failed cycles had been cancelled because of 'inadequately' thin endometrium (Table I) .
In considering our results, it also appears important to, once more, consider the patient population in which these results were obtained: These were women of advanced age (40.5 + 6.6 years), with prior IVF failures at other centers (2.0 + 2.1) and diminished functional ovarian reserve in 76.2% of cases. These women nevertheless reached the stage of ovulation induction with hCG but at that point were diagnosed with treatment-resistant thin endometrium. Options at that point were limited to: (i) the patient agreeing to participate in the center's registered prospectively RCT (ClinicalTrials.gov ID, NCT01202643); (ii) cycle cancellation; (iii) embryo transfer into an inadequate endometrium (,7 mm) or (iv) off-label use of G-CSF, based on the center's prior experience with four patients (Gleicher et al., 2011) . None of the patients described here consented to participation in the clinical trial, and all the 21 selected option (iv) and provided appropriate informed consent.
These results raise the question of how G-CSF expands endometrial thickness in such a short time? In our initial publication, we reported that a growth spurt in endometrial thickness can be observed within 48 h of G-CSF administration (Gleicher et al., 2011) . This was confirmed here, as all but three patients reached a minimal thickness of 7 mm within 48 h, by the time of oocyte retrieval. The remaining three patients reached this minimal thickness, after a second infusion, by the day of embryo transfer (Day 3).
How G-CSF accomplishes this is, however, unknown. Surprisingly, little is known about how G-CSF impacts on the endometrium. G-CSF is a glycoprotein with growth factor and cytokine functions and is produced in different tissues/cells, including endothelium, macrophages and in other immunocytes. In the central nervous system, G-CSF not only acts as a proliferant by inducing neurogenesis but also has anti-apoptotic functions (Schneider et al., 2005) . It, therefore, has been proposed as a potential therapeutic agent in neurodegenerative diseases (Pitzer et al., 2008) .
Investigating the effect of G-CSF on proliferation and differentiation of normal human endometrial stromal cells, Tanaka et al. (2000) concluded that G-CSF enhances cAMP-mediated decidualization of human endometrial stromal cells in both an autocrine and a paracrine fashion. In a follow-up study, the same authors demonstrated that macrophage (M)-CSF enhances G-CSF secretion from unstimulated human endometrial stromal cells but not from 8-BR-cAMP-stimulated cells (Tanaka and Umesaki, 2003) . Fahey et al. (2005) reported that, among other cytokines and chemokines, G-CSF and granulocytemacrophage CSF (GM-CSF) are secreted apically in polarized epithelial cells.
In clinical reproduction, G-CSF has been proposed as a treatment for implantation failure and repeated miscarriages (Scarpellini and Sbracia, 2009; Würfel et al., 2010; Toth et al., 2011)) , two indications for which a US patent has been issued (United States Patent, 2008) . How these widely divergent alleged benefits are achieved is, however, still unknown. The patent mostly assumes immunological processes, which cannot explain the proliferative effects on the endometrium observed here.
G-CSF and GM-CSF appear to be involved in a wide variety of reproductive functions: Yanagi et al. (2002) reported cyclic changes of G-CSF mRNA in follicular fluid during the menstrual cycle. Salmassi et al. (2004) described G-CSG and its receptor in human luteinized granulosa cells. G-CSF in follicular fluid has been proposed as useful biomarker of oocyte competence before fertilization (Lédée et al., 2011) .
From basic research, slightly more data on the effects of GM-CSF on endometrium have been obtained. Zhao and Chegini (1999) suggested that expression of GM-CSF and its receptor during the menstrual cycle implies an autocrine and paracrine function of GM-CSF in the endometrium. Chegini et al. (1999) reported that GM-CSF is not mitogenic for endometrial cells, whether epithelial or glandular, but in an interactive fashion with transforming growth factor (TGF)-b1 it regulates its own expression and the expression of TGF-b1 in the endometrium. In mice GM-CSF has been suggested as an essential regulator of T cell activation competence in uterine dendritic cells during early pregnancy (Moldenhauer et al., 2010) .
Claims have been made that supplementation of embryo growth media with GM-CSF promotes human embryo development to blastocyst stage (Sjö blom et al., 1999 ). An embryo growth medium supplemented with GM-CSF became available commercially in Europe in 2011. Its approval in the USA is expected in late 2012, with claims of a 44% improvement in implantation rate (EmbroGen w , Måløv. Denmark) [http://www.origio.com http://www.origio.com/ products/medicult%20,edia/embryogen.aspx (13 May 2012, date last accessed)]. Takasaki et al. (2008) reported that use of M-CSF in combination with human menopausal gonadotrophin in poor responders improves follicle development.
G-CSF, GM-CSF and M-CSF are, however, distinct: G-CSF, in principle, facilitates stem cell and progenitor proliferation in neutrophilic granulocytes, while GM-CSF facilitates proliferation and differentiation in granulocytes, macrophages and eosinophils. Because of proliferative effects on fibroblasts, one, therefore, can hypothesize that GM-CSF may expand endometrial thickness even more than G-CSF. Such studies remain, however, to be performed. Moreover, because it is unknown how G-CSF achieves the rapid proliferation of endometrial architecture, any potential effects of M-CSF or GM-CSF at this point are just conjecture.
The matter is further complicated by the fact that one can also not rule out possible synergistic effects between G-CSF and sildenafil citrate (Viagra TM ), which all the patients in the study received before and during G-CSG administration. A better understanding of the action of G-CSF on the endometrium would, obviously, greatly strengthen the credibility of its utility in this indication.
The cohort of patients presented here, thus, provides further evidence that G-CSF perfusion of the endometrium may offer an effective last resort for treatment of thin endometrium that is resistant to more traditional treatment modalities. This observation, however, has to be confirmed by larger studies, preferably in the form of a prospective RCT.
The study, however, raises a number of additional questions: How does G-CSF thicken the endometrium within such a short time interval? As we have performed no dosageing studies, the question arises as to whether the treatment protocol we are utilizing is maximal? One has to assume that improvements should be possible.
In earlier noted treatments for implantation failure and repeat miscarriages, G-CSF has been administered by the subcutaneous rather than the intrauterine route (Scarpellini and Sbracia, 2009; Würfel et al., 2010; Toth et al., 2011) . Which delivery method for the drug is superior remains to be determined. Moreover, in these studies G-CSF was administered for much longer time periods, suggesting that more frequent administration (maybe daily) may have superior benefits. Finally, as already noted, it is tempting to hypothesize that M-CSF or GM-CSF may have even better effectiveness.
Considering the age of our patient population, with a mean of 40.5 years and with established diminished ovarian reserve in 76.2% of women, and taking their endometrial characteristics into account, the ongoing clinical pregnancy rate of 19.1% has to be considered quite remarkable. Our 2011 ongoing clinical pregnancy rate for all women at age 41 years in a very similar patient population was 25% (www.centerforhumanreprod.com). While our data are obviously preliminary, we would suggest that administration of G-CSF in women with treatment-resistant endometrium restores potential female fertility to a significant degree. Considering that the natural conception rate in a general infertile population has been estimated at 1% per month (Gleicher et al., 1996) , it is reasonable to assume that the pregnancy chance in a patient population, such as that presented here, is unlikely to be more than one-tenth of that figure. In an 18-month period, the time that patients were recruited for this study, one therefore, optimistically, could expect only a spontaneous pregnancy rate of, at most, ca. 3.6%.
This observation once again raises the question of whether, beyond endometrial expansion, G-CSF can, in general, beneficially affect implantation and pregnancy rates in women undergoing IVF. We hope to be able to answer at least this last question quite soon, upon completion of our ongoing clinical trial.
